- Joined
- Jan 15, 2019
- Messages
- 51,527
- Reaction score
- 44,742
- Location
- Texas
- Gender
- Male
- Political Leaning
- Slightly Liberal
This is pretty exciting.. If this pans out, this could speed up ending the pandemic...
A pair of dedicated Texas researchers are poised to play a significant part in making that happen. Dr. Peter Hotez and Maria Elena Bottazzi, co-directors of the Texas Children’s Hospital Center for Vaccine Development, in Houston, have helped develop a COVID-19 vaccine that’s likely to become one of the cheapest and most accessible vaccines throughout the world. It’s just entered phase three clinical trials in India, and it could prove vital to low-income countries that can’t afford to purchase or manufacture the sort of vaccines that are widely available in the United States.
“Right now, nobody in Africa is getting vaccinated, and not many more are in Latin America or Southeast Asia, because we don’t have a scaled-up vaccine for low- and middle-income countries,” says Hotez, also dean of the National School of Tropical Medicine at Baylor College of Medicine. “We’re hoping this one will fill the gap. We think it’s going to be one of the real, truly low-cost people’s vaccines that could be used to vaccinate the world.”
What makes their vaccine, Corbevax, so special is that, well, it’s not that special. Instead of relying on newer—and more expensive—technology, such as mRNA (as in the Pfizer and Moderna vaccines) or adenovirus vectors (the Johnson & Johnson and AstraZeneca vaccines), Corbevax is a more conventional recombinant protein vaccine. It’s designed the same way as the hepatitis B vaccine and others that have been in use for decades. Yet testing so far suggests that Corbevax is about as effective as its newer, fancier counterparts, with an efficacy over 85 percent.
www.texasmonthly.com
A pair of dedicated Texas researchers are poised to play a significant part in making that happen. Dr. Peter Hotez and Maria Elena Bottazzi, co-directors of the Texas Children’s Hospital Center for Vaccine Development, in Houston, have helped develop a COVID-19 vaccine that’s likely to become one of the cheapest and most accessible vaccines throughout the world. It’s just entered phase three clinical trials in India, and it could prove vital to low-income countries that can’t afford to purchase or manufacture the sort of vaccines that are widely available in the United States.
“Right now, nobody in Africa is getting vaccinated, and not many more are in Latin America or Southeast Asia, because we don’t have a scaled-up vaccine for low- and middle-income countries,” says Hotez, also dean of the National School of Tropical Medicine at Baylor College of Medicine. “We’re hoping this one will fill the gap. We think it’s going to be one of the real, truly low-cost people’s vaccines that could be used to vaccinate the world.”
What makes their vaccine, Corbevax, so special is that, well, it’s not that special. Instead of relying on newer—and more expensive—technology, such as mRNA (as in the Pfizer and Moderna vaccines) or adenovirus vectors (the Johnson & Johnson and AstraZeneca vaccines), Corbevax is a more conventional recombinant protein vaccine. It’s designed the same way as the hepatitis B vaccine and others that have been in use for decades. Yet testing so far suggests that Corbevax is about as effective as its newer, fancier counterparts, with an efficacy over 85 percent.

Can This Houston-Born COVID Vaccine Save the Developing World?
For low-income countries, the less-expensive, easier-to-make Corbevax could prove a godsend.
